Suppr超能文献

GLP-1 类药物的发现和开发彻底改变了肥胖症的治疗方法。

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.

机构信息

HHMI at Rockefeller University, New York, NY 10065.

出版信息

Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2415550121. doi: 10.1073/pnas.2415550121. Epub 2024 Sep 19.

Abstract

The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity. Each of the three had a distinct set of skills that made this advance possible; Habener is an endocrinologist and molecular biologist, Mojsov is a peptide chemist, and Knudsen is a pharmaceutical scientist. Their collective efforts have done what few thought possible-the development of highly effective medicines for reducing weight. Their research has also solved a mystery that began more than a century ago.

摘要

2024 年拉斯克-德贝基临床医学研究奖授予 Joel Habener、Svetlana Mojsov,以表彰他们发现了一种新的激素 GLP-1(7-37),以及 Lotte Knudsen 在开发这种激素的长效版本作为肥胖症治疗方法方面所做的贡献。这三位科学家都有独特的技能,使得这一进展成为可能;Habener 是内分泌学家和分子生物学家,Mojsov 是肽化学家,Knudsen 是药物科学家。他们的共同努力实现了很少有人认为可能的事情——开发出高效的减肥药。他们的研究还解决了一个一个多世纪前就开始的谜团。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c4e/11441540/b0da3458f2a2/pnas.2415550121fig01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验